全球产后出血治疗设备市场 – 行业趋势及 2030 年预测

产后出血治疗设备市场分析及规模

妊娠相关并发症（如大婴儿、子宫倒置和多胎妊娠等）的患病率不断上升，是产后出血治疗设备市场发展的关键驱动因素。此外，孕妇产后出血风险因素增加的各种原因（如贫血病例增加、创伤和子宫收缩乏力等）也是产后出血治疗设备市场整体发展的关键驱动因素。

Data Bridge Market Research 分析，产后出血治疗设备市场在 2022 年为 7.726 亿美元，预计到 2030 年将达到 10.0953 亿美元，在 2023 年至 2030 年的预测期内复合年增长率为 3.4%。除了对市场价值、增长率、细分、地理覆盖范围和主要参与者等市场情景的见解外，Data Bridge Market Research 策划的市场报告还包括深度专家分析、患者流行病学、管道分析、定价分析和监管框架。

产后出血治疗设备市场范围和细分  

市场定义

The most common type of obstetric haemorrhage and one of the leading causes of maternal mortality is postpartum haemorrhage (PPH). PPH refers to blood loss during vaginal or cesarean delivery. The type of postpartum haemorrhage is determined by the amount of blood lost. Primary PPH is defined as blood loss of less than 500 mL, while secondary PPH has defined as blood loss greater than 500 mL.

Postpartum Hemorrhage Treatment Devices Market Dynamics

Drivers

• Rise in complications such as obstetric hemorrhage

The market for postpartum haemorrhage devices is expanding due to an increase in complications such as acute postpartum haemorrhage. Obstetric haemorrhage is the most common and dangerous complication of childbirth. PPH is traditionally defined as blood loss of more than 500 mL estimated during vaginal delivery or more than 1000 mL estimated during caesarean delivery. This was defined in 2017 by the American College of Obstetrics and Gynecology as an accumulation of blood loss of more than 1000 mL with signs and symptoms of hypovolemia within 24 hours of the birth procedure, regardless of delivery mode.

Opportunities

• Growing investment in healthcare sector in developed and developing countries

Governments in developing countries such as India and China invest heavily in their healthcare sectors. For example, the Indian health tech industry was estimated to be worth $1.9 billion in 2020. With a CAGR of 39%, it is expected to reach $ 5 billion by 2023. In 2018, the Indian digital healthcare market was valued at USD 1.50 billion, and it is expected to grow to USD 6.26 billion by 2024. The expansion of the healthcare industry is expected to benefit the postpartum haemorrhage devices market.

Restraints/Challenges

• Inaccuracies in measuring blood loss in obstetric Hemorrhage

Postpartum haemorrhage is the leading cause of maternal death in the United States, accounting for approximately 11% of all maternal deaths. Significantly, obstetric haemorrhage is responsible for 54-93% of maternal deaths. According to studies, healthcare providers' inaccurate estimation of actual blood loss at the time of birth and in the immediate postpartum period is a major cause of delayed haemorrhage response. Underestimation of blood loss leads healthcare providers to believe that deployment of postpartum haemorrhage devices is unnecessary, limiting the use of postpartum haemorrhage devices.

This postpartum hemorrhage treatment devices market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the postpartum hemorrhage treatment devices market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on the Postpartum Hemorrhage Treatment Devices Market

The COVID-19 pandemic had a negative impact on people's health and the global economy. It has affected entire economies, businesses, and individuals' careers and lives. Millions of people died as a result of the outbreak around the world. As businesses shift their focus away from growth prospects and toward implementing exceptional measures to mitigate the negative impact of the COVID-19 pandemic, the stress of maintaining pre-COVID revenue levels has become the new normal. The market for postpartum haemorrhage devices is expected to grow in response to the COVID-19 outbreak. Infection with Covid-19 increases the risk of pregnancy complications such as postpartum hemorrhage, which helps the market grow by increasing the number of PPH patients.

Recent Developments

• In 2021, Merck announced the acquisition of Alydia Health for its planned Organon spinoff, to improve women's health by addressing unmet medical needs in maternal health and facilitate safer delivery.
• In 2021, Stryker announced the acquisition of Gauss Surgical, a medical device company that developed TritonTM, an artificial intelligence-powered platform for real-time blood loss monitoring during surgery. Triton has demonstrated maternity and surgical care benefits by detecting haemorrhage and intervening sooner.

Global Postpartum Hemorrhage Treatment Devices Market Scope

The postpartum hemorrhage treatment devices market is segmented on the basis of type, end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Uterine Balloon Tamponade
• Foley Catheter
• Balloon Tamponade
• Condom Catheter
• Others
• Uniject Prefilled Injection System
• Non-Pneumatic Anti Shock Garment

End User

• Hospitals
• Clinics
• Others

Postpartum Hemorrhage Treatment Devices Market Regional Analysis/Insights

The postpartum hemorrhage treatment devices market is analyzed and market size insights and trends are provided by country, type, end-user as referenced above.

产后出血治疗设备市场报告涉及的国家包括北美洲的美国、加拿大和墨西哥、欧洲的德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、欧洲其他地区、亚太地区 (APAC) 的中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太地区 (APAC) 的其他地区、中东和非洲 (MEA) 的其他地区、南美洲的巴西、阿根廷和南美洲其他地区。

北美凭借其完善的医疗保健基础设施和优惠的报销政策占据产后出血治疗设备市场的主导地位。

由于出血发病率的不断增加，预计亚太地区在 2023 年至 2030 年的预测期内将以最高的增长率增长。

报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测单个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。

医疗保健基础设施增长安装基础和新技术渗透

产后出血治疗设备市场还为您提供每个国家/地区资本设备医疗支出增长、产后出血治疗设备市场不同类型产品的安装基数、使用生命线曲线的技术影响以及医疗监管情景的变化及其对产后出血治疗设备市场的影响的详细市场分析。数据适用于 2011-2021 年的历史时期。

产后出血治疗设备竞争格局及市场份额分析

产后出血治疗设备市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对产后出血治疗设备市场的关注有关。

产后出血治疗设备市场的一些主要参与者包括：

• BD（美国）
• 通用电气（美国）
• BACTIGUARD AB（瑞典）
• 博恩医疗保健股份有限公司 (中国)
• 库克（美国）
• RevMedx（美国）
• SARA 医疗保健（印度）
• Inpress Technologies Inc.（美国）
• Vitality Medical（美国）
• Angiplast Pvt. Ltd. (印度)
• Davol（印度）
• 第三石材设计（美国）
• Teleflex Incorporated（美国）
• 犹他医疗产品公司（美国）
• ZOEX（美国）

SKU-64046